SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 78,400
-600 (-0.76%)
At close: Aug 3, 2026
SK Biopharmaceuticals Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 790,250 | 706,741 | 547,596 | 354,892 | 246,179 | 418,645 |
Revenue Growth | 36.72% | 29.06% | 54.30% | 44.16% | -41.20% | 1510.23% |
Gross Profit Gross Profit Growth | 743,515 | 663,840 | 504,495 | 320,809 | 208,411 | 396,309 |
Operating Income Operating Income Growth | 268,035 | 203,938 | 96,340 | -37,522 | -131,078 | 94,958 |
Net Income Net Income Growth | 348,808 | 266,950 | 240,738 | -32,883 | -139,431 | 64,846 |
Earnings Per Share EPS Growth | 4452.45 | 3408.75 | 3074.04 | -419.89 | -1780.43 | 828.03 |
EPS Growth | 38.76% | 10.89% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Korea Korea Growth | - | 100 | 6,006 | - | 214,941 | 455,255 |
United States of America United States of America Growth | 707,124 | 642,656 | 438,662 | 288,788 | 388,212 | 267,220 |
Switzerland Switzerland Growth | 37,805 | 33,249 | 42,334 | 12,774 | - | - |
Cayman Islands Cayman Islands Growth | 6,226 | 4,175 | 35,843 | 14,150 | - | - |
Japan Japan Growth | 14,489 | 12,913 | 10,243 | 12,772 | - | - |
Malta Malta Growth | 12,716 | 11,380 | 12,259 | 12,704 | - | - |
Other Countries Other Countries Growth | 11,890 | 2,268 | 2,249 | 13,703 | - | - |
Total Total Growth | 790,250 | 706,741 | 547,596 | 354,892 | 246,179 | 418,645 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 310,861 | 309,482 | 324,489 | 241,118 | 305,454 | 334,339 |
Total Debt Total Debt Growth | 49,981 | 48,920 | 184,482 | 178,050 | 155,896 | 15,738 |
Net Cash (Debt) Net Cash Growth | 260,880 | 260,562 | 140,007 | 63,068 | 149,558 | 318,602 |
Net Cash Growth | 81.12% | 86.11% | 121.99% | -57.83% | -53.06% | -13.78% |
Net Cash Per Share Net Cash Per Share Growth | 3330.07 | 3327.18 | 1787.78 | 805.33 | 1909.74 | 4068.30 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 166,965 | 176,334 | 94,900 | -94,201 | -159,920 | -92,872 |
Capital Expenditures CapEx Growth | -8,186 | -6,892 | -1,395 | -2,385 | -4,911 | -4,316 |
Free Cash Flow Free Cash Flow Growth | 158,779 | 169,442 | 93,505 | -96,586 | -164,831 | -97,188 |
Free Cash Flow Growth | 61.43% | 81.21% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 94.09% | 93.93% | 92.13% | 90.40% | 84.66% | 94.66% |
Operating Margin | 33.92% | 28.86% | 17.59% | -10.57% | -53.24% | 22.68% |
Pretax Margin | 29.17% | 21.35% | 13.26% | -12.36% | -57.87% | 17.03% |
Profit Margin | 44.14% | 37.77% | 43.96% | -9.27% | -56.64% | 15.49% |
FCF Margin | 20.09% | 23.97% | 17.08% | -27.22% | -66.96% | -23.21% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.74 | 36.55 | 36.14 | - | - | 117.39 |
Forward PE | 18.94 | 39.32 | 73.81 | - | - | - |
P/FCF Ratio | 38.96 | 57.59 | 93.05 | - | - | - |
PS Ratio | 7.83 | 13.81 | 15.89 | 22.16 | 22.94 | 18.18 |